Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 114

1.

Re: tumor markers in the diagnosis of primary bladder cancer. A systematic review.

Casella R.

J Urol. 2004 Jun;171(6 Pt 1):2383-4. No abstract available.

PMID:
15126839
2.

Urinary markers in bladder cancer.

Vrooman OP, Witjes JA.

Eur Urol. 2008 May;53(5):909-16. Review.

PMID:
18162285
3.

Bladder cancer markers in patient management: the current perspective.

Schmitz-Dräger BJ, Fradet Y, Grossman HB.

World J Urol. 2008 Feb;26(1):1-3. No abstract available.

PMID:
18060549
4.

The use of urine-based biomarkers in bladder cancer.

Grossman HB, Blute ML, Dinney CP, Jones JS, Liou LS, Reuter VE, Soloway MS.

Urology. 2006 Mar;67(3 Suppl 1):62-4. No abstract available.

PMID:
16530080
5.

Urinary bladder tumor markers.

Lokeshwar VB, Selzer MG.

Urol Oncol. 2006 Nov-Dec;24(6):528-37. Review.

PMID:
17138134
7.

Markers in bladder cancer--issues to consider.

Droller MJ.

J Urol. 1998 Dec;160(6 Pt 1):2009-10. No abstract available.

PMID:
9817311
8.

Urine detection of survivin and diagnosis of bladder cancer.

Moore M.

J Insur Med. 2001;33(2):202-3. No abstract available.

PMID:
11510521
9.

Bladder tumor markers: a review of the literature.

Volpe A, Racioppi M, D'Agostino D, Cappa E, Gardi M, Totaro A, Pinto F, Sacco E, Marangi F, Palermo G, Bassi PF.

Int J Biol Markers. 2008 Oct-Dec;23(4):249-61. Review.

PMID:
19199274
10.

Can urinary biomarkers replace cystoscopic examination in bladder cancer surveillance?

Yutkin V, Nisman B, Pode D.

Expert Rev Anticancer Ther. 2010 Jun;10(6):787-90. doi: 10.1586/era.10.75. No abstract available.

PMID:
20553203
11.

How are we going to discover new cancer biomarkers? A proteomic approach for bladder cancer.

Diamandis EP.

Clin Chem. 2004 May;50(5):793-5. No abstract available.

12.

Urine markers for bladder cancer surveillance: a systematic review.

Ratliff TL.

J Urol. 2005 Nov;174(5):2065-6. Review. No abstract available.

PMID:
16217395
13.

Screening for bladder cancer using urine-based tumor markers.

Svatek RS, Lotan Y, Karakiewizc PI, Shariat SF.

Minerva Urol Nefrol. 2008 Dec;60(4):247-53. Review.

PMID:
18923361
14.

Diagnostic potential in bladder cancer of a panel of tumor markers (calreticulin, gamma -synuclein, and catechol-o-methyltransferase) identified by proteomic analysis.

Iwaki H, Kageyama S, Isono T, Wakabayashi Y, Okada Y, Yoshimura K, Terai A, Arai Y, Iwamura H, Kawakita M, Yoshiki T.

Cancer Sci. 2004 Dec;95(12):955-61.

15.

Re: The BTA stat test is nonspecific for hematuria: an experimental hematuria model.

Kinders RJ, Landicho H.

J Urol. 2002 Dec;168(6):2556; author reply 2556-7. No abstract available.

PMID:
12441978
16.

[Telomerase activity: a molecular marker for early diagnosis of bladder tumor].

Calistri D, Sanchini A, Amadori D, Silvestrini R.

Recenti Prog Med. 2007 Feb;98(2):74-8. Italian.

PMID:
17439065
17.

Potential of urinary biomarkers in early bladder cancer diagnosis.

Lam T, Nabi G.

Expert Rev Anticancer Ther. 2007 Aug;7(8):1105-15. Review.

PMID:
18028019
18.

Urinary markers in bladder cancer.

Bailey MJ.

BJU Int. 2003 Jun;91(9):772-3. No abstract available.

19.

[Value of urinary markers in the diagnosis and follow-up of urothelial bladder tumours].

Campos-Fernandes JL, Descotes F, André J, Perrin P, Devonec M, Ruffion A.

Prog Urol. 2007 Feb;17(1):23-34. Review. French.

PMID:
17373233
20.

The simultaneous use of telomerase, cytokeratin 20 and CD4 for bladder cancer detection in urine.

Siracusano S, Niccolini B, Knez R, Tiberio A, Benedetti E, Bonin S, Ciciliato S, Pappagallo GL, Belgrano E, Stanta G.

Eur Urol. 2005 Mar;47(3):327-33.

PMID:
15716196
Items per page

Supplemental Content

Support Center